Navigation Links
Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus

British Drug company, PowerMed is seeking approval for conducting the first human trials of experimental vaccine against the deadly strain of avian flu virus H5N1//.

The World Health Organisation has reported 97 human cases of avian flu since December 2003, with at least 53 deaths.

The company has submitted its plans for the trial to the UK Medicines and Healthcare Products Regulatory Agency. The Agency is expected to approve the vaccine for the trial to proceed at a London hospital.

While the government has stockpiled antiviral drugs Tamiflu and Relenza against avian flu the vaccine could help to limit the infection's spread if a pandemic strain emerges. Unlike most other conventional vaccines that use weakened strains or fragments of the harmful virus, this test vaccine uses strands of DNA , making it a faster and more cost effective option.

During the trial, the volunteers are expected to be vaccinated with a handheld device that will blast harmless, microscopic gold particles coated in the vaccine into the upper arm at supersonic speeds.

Earlier this year tests of a DNA vaccine that was designed to give protection against seasonal flu showed that it offered 100% protection, based on the immune response of volunteers. The DNA vaccine against avian flu has been tested only in animals, so far, where it has proved successful.

According to John Beadle, chief medical officer of the Oxford-based company PowderMed, ‘Our tests have shown that it stops the infection entirely, to the point that we can't even measure the virus in the animals afterwards.’

The company's research has suggested that humans would require two doses of the vaccine, a prime and a boost. Half a kilogram of DNA would suffice for two doses of the vaccine for everyone in Britain.

The details of the trial are put up on the government's website, Clinicaltrials.gov where the company has statecd that was seeking 75 voluntee rs for the trial at Guy's drug research unit in London.

If the trial goes ahead as planned, volunteers will be tested over several months to monitor how long the vaccine remains effective. Preliminary results are expected in January next year.


'"/>




Related medicine news :

1. Problems Of a Growing Company
2. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Elderly People Prefer The Company Of Pet Dogs
5. Ossur Acquires the U.S. Orthopaedics Company
6. Britain Approves Indian Company For Supplying Medicines
7. Drug Company Admits Knowledge Of Side Effects In Monkeys
8. Ranbaxy Expands By Acquiring A Generic Company In Belgium
9. Indian Training Company To Train Children In Dubai, Sharjah
10. GE Healthcare to Acquire Swedish Medical Company
11. New Company Will Seek Drugs Against Diabetes and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... FL (PRWEB) , ... April 24, 2017 , ... ... Paul Gallardo, DDS, PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 ... 2017. , The Oral Reconstruction Foundation will present its annual Global Symposium at ...
(Date:4/24/2017)... WA (PRWEB) , ... April 24, 2017 , ... ... leading lifestyle brands, work wear distributors and International relief organizations across the globe ... The company also offers lifestyle and work wear collections via insectshield.com . ...
(Date:4/24/2017)... ... April 24, 2017 , ... A 2-in-1 bottleless water ... place. From 101 Water Texas, here are the ways in which this technology ... continuous supply of pure, fresh, oxygenated water, with both cold and hot options. ...
(Date:4/23/2017)... ... 2017 , ... Altura Communication Solutions, a nationwide provider of ... and SMB specialization. Altura is now qualified to sell, install and support ... Certification, Altura fulfilled the training and exam requirements for the Cisco Small Medium ...
(Date:4/22/2017)... Philadelphia, PA (PRWEB) , ... ... ... Small Business Administration of Eastern Pennsylvania has named PROSHRED® Security of ... Pennsylvania-native Ginny Heron-Doerr, PROSHRED® Philadelphia specializes in providing information destruction ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... AMSTERDAM , April 20, 2017  AbbVie ... that 99 percent (n=145/146) of chronic hepatitis C ... 4, 5 or 6 and compensated cirrhosis (Child-Pugh ... post-treatment (SVR 12 ) with its investigational, pan-genotypic ... rates were seen following 12 weeks of ...
(Date:4/20/2017)... , April 20, 2017 NeuroVive ... ("NeuroVive") today announced positive preclinical results demonstrating ... compound for non-alcoholic steatohepatitis (NASH), in an ... NV556 has previously shown similar ... model. Today, NeuroVive,s scientists present novel data ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
Breaking Medicine Technology: